8-K: MaxCyte Announces Preliminary 2024 Financial Results, Core Revenue Growth Reported

MaxCyte reports preliminary unaudited financial results for Q4 and full year 2024, showing core revenue growth and increased cash reserves.

Summary

• MaxCyte has released preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
• Core revenue for the fourth quarter is expected to be between $8.3 million and $8.5 million, compared to $7.2 million in the same period of 2023.
• Full-year core revenue is projected to be between $32.2 million and $32.4 million, up from $29.8 million in 2023, representing an 8 to 9% growth.
• The company's total cash, cash equivalents, and investments are expected to be approximately $190 million as of December 31, 2024.
• This is an increase from the initial guidance of $175 million and updated guidance of $185 million, and a decrease from $211 million at the end of 2023.
• SPL program-related revenue and total revenue for the fourth quarter and full year 2024 will be reported in March 2025.
• The company increased its number of SPL customers by six in 2024 and supported the commercial launch of the first non-viral gene-edited cell therapy product approved by the FDA.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the better-than-expected cash position, core revenue growth, and the company's involvement in a significant industry milestone. However, the preliminary nature of the results and the decrease in overall cash temper the optimism slightly.

Positives

• Core revenue is showing growth both in the fourth quarter and for the full year.
• The company's cash position is stronger than previously guided.
• MaxCyte has increased its customer base in the SPL program.
• The company has supported a significant milestone in the cell therapy industry with the launch of the first non-viral gene-edited cell therapy product.

Negatives

• Total cash, cash equivalents, and investments decreased from $211 million at the end of 2023 to approximately $190 million at the end of 2024.
• The reported results are preliminary and unaudited, and may change after the completion of the closing processes.

Risks

• The preliminary financial results are subject to change upon completion of the company's closing processes and audit.
• The company's future performance is subject to risks and uncertainties detailed in their SEC filings.
• The cell therapy industry is subject to various risks and uncertainties that could impact MaxCyte's performance.

Future Outlook

The company is confident in its opportunities for the future, with an improving operating environment in the cell therapy industry as they move into 2025.

Management Comments

• Maher Masoud, President and CEO of MaxCyte, stated that the operating environment in the cell therapy industry is improving as we move into 2025.
• Maher Masoud also mentioned that they remain confident in the opportunity that exists for MaxCyte in the years ahead.
• Management highlighted that in 2024, they increased the number of SPL customers by six, supported the commercial launch of the first non-viral gene edited cell therapy product approved by the FDA, and returned to healthy revenue growth while streamlining operations.

Industry Context

MaxCyte's results reflect the broader trends in the cell therapy industry, which is experiencing growth and innovation, particularly in gene-edited therapies. The company's technology is positioned to support this growth.

Comparison to Industry Standards

• MaxCyte's 8-9% core revenue growth is a positive sign in the context of the broader biotech industry, which has seen varied performance.
• Companies like CRISPR Therapeutics and Editas Medicine, which are also involved in gene editing, have seen significant fluctuations in their financial performance, making MaxCyte's steady growth notable.
• The increase in SPL customers and support for the first non-viral gene-edited cell therapy product puts MaxCyte in a strong position compared to competitors in the cell engineering space.
• The cash position of $190 million provides a solid foundation for future growth and investment, which is a key metric for biotech companies.

Stakeholder Impact

• Shareholders will likely view the preliminary results positively due to the revenue growth and strong cash position.
• Employees may be encouraged by the company's growth and positive outlook.
• Customers and partners may see MaxCyte as a reliable and innovative technology provider.
• Creditors may view the company as financially stable due to its cash reserves.

Next Steps

• The company will release its audited financial statements for the quarter and fiscal year ended December 31, 2024, in March 2025.
• The company will report SPL program-related revenue and total revenue for the fourth quarter and full year 2024 in March 2025.

Key Dates

Keywords

cell therapy, core revenue, financial results, SPL program, cash reserves, electroporation, gene editing, biotechnology